{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:06:46Z","timestamp":1789092406053,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The National Key Research and Development Program","award":["2022YFC2603500, 2022YFC2603505,2023YFC2306901,2023YFC2308105"],"award-info":[{"award-number":["2022YFC2603500, 2022YFC2603505,2023YFC2306901,2023YFC2308105"]}]},{"name":"Beijing Research Ward Excellence Program, BRWEP","award":["BRWEP2024W102170101"],"award-info":[{"award-number":["BRWEP2024W102170101"]}]},{"name":"he capital health research and development of special public health project","award":["2022-1-2172"],"award-info":[{"award-number":["2022-1-2172"]}]},{"name":"Beijing Municipal Health Commission high-level public health technical personnel construction project","award":["discipline leader -03-26, discipline backbone-02-28"],"award-info":[{"award-number":["discipline leader -03-26, discipline backbone-02-28"]}]},{"name":"Beijing Hospitals Authority \"peak\" talent training program","award":["DFL20241803"],"award-info":[{"award-number":["DFL20241803"]}]},{"DOI":"10.13039\/501100009331","name":"Beijing Hospitals Authority Clinical medicine Development of special funding support","doi-asserted-by":"crossref","award":["ZLRK202301"],"award-info":[{"award-number":["ZLRK202301"]}],"id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The relationship between changes in hepatitis B surface antibody (HBsAb) levels and hepatic adverse events after hepatitis B surface antigen (HBsAg) clearance remains unclear. This study aimed to investigate the correlation between HBsAb level changes and hepatic adverse events in non-cirrhotic patients following HBsAg clearance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed patients with HBsAg seroclearance achieved via pegylated interferon-alpha (Peg-IFN\u03b1) therapy in the Department of Hepatology II at Beijing Ditan Hospital, Capital Medical University, from October 2008 to December 2023. Participants were stratified by baseline HBsAb levels into negative (&lt;\u200910 mIU\/mL), low (10\u2013100 mIU\/mL), medium (100\u20131000 mIU\/mL), and high (\u2265\u20091000 mIU\/mL) groups. Based on HBsAb trends during follow-up, patients were categorized into declining, stable, and rising groups. The primary endpoint was the incidence of hepatic adverse events after HBsAg clearance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 390 patients were included, with a median age of 38 (32\u201344) years and a median follow-up of 53.50 (11.00\u2013173.00) months. During follow-up, 4 cases of hepatic adverse events occurred, all in the declining group (4 cases, 3.05%), while none were observed in the stable or rising groups (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.018). Changes in HBsAb levels were inversely correlated with the incidence of hepatic adverse events (\n                      <jats:italic>rs<\/jats:italic>\n                      = -0.125,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.014).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Declining HBsAb levels after HBsAg clearance may be associated with an increased risk of hepatic adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial<\/jats:title>\n                    <jats:p>\n                      This study was registered at ClinicalTrials.gov (ID: NCT04301908; registration date: 03\/06\/2020;\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/register.clinicaltrials.gov\/\" ext-link-type=\"uri\">https:\/\/register.clinicaltrials.gov\/<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-13791-9","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T02:52:17Z","timestamp":1782442337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between changes in HBsAb levels and hepatic adverse events after HBsAg clearance in non-cirrhotic chronic hepatitis B patients"],"prefix":"10.1186","volume":"26","author":[{"given":"Wen","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linmei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuojie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"issue":"3","key":"13791_CR1","first-page":"457","volume":"26","author":"H You","year":"2023","unstructured":"You H, Wang F, Li T, et al. Guidelines for the prevention and treatment of chronic hepatitis B: 2022 update. J Pract Hepatol. 2023;26(3):457\u201378. 10.3760.","journal-title":"J Pract Hepatol"},{"issue":"1","key":"13791_CR2","doi-asserted-by":"publisher","first-page":"99209","DOI":"10.4254\/wjh.v17.i1.99209","volume":"17","author":"T Kanda","year":"2025","unstructured":"Kanda T, Sasaki-Tanaka R, Tsuchiya A, et al. Hepatitis B virus infection and its treatment in Eastern Ethiopia. World J Hepatol. 2025;17(1):99209. https:\/\/doi.org\/10.4254\/wjh.v17.i1.99209.","journal-title":"World J Hepatol"},{"issue":"4","key":"13791_CR3","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u201399. https:\/\/doi.org\/10.1002\/hep.29800.","journal-title":"Hepatology"},{"issue":"2","key":"13791_CR4","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021.","journal-title":"J Hepatol"},{"issue":"2","key":"13791_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jhep.2024.08.016","volume":"82","author":"MH Hur","year":"2025","unstructured":"Hur MH, Yip TC, Kim SU, et al. A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B. J Hepatol. 2025;82(2):235\u201344. https:\/\/doi.org\/10.1016\/j.jhep.2024.08.016.","journal-title":"J Hepatol"},{"issue":"4","key":"13791_CR6","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s12328-024-01984-1","volume":"17","author":"T Sasaki","year":"2024","unstructured":"Sasaki T, Kakisaka K, Miyasaka A, et al. Spontaneous reactivation of hepatitis B virus with multiple novel mutations in an elderly patient with resolved hepatitis B virus infection. Clin J Gastroenterol. 2024;17(4):683\u201390. https:\/\/doi.org\/10.1007\/s12328-024-01984-1.","journal-title":"Clin J Gastroenterol"},{"issue":"Suppl 1","key":"13791_CR7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/jvh.13151","volume":"26","author":"MH Li","year":"2019","unstructured":"Li MH, Yi W, Zhang L, et al. Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy. J Viral Hepat. 2019;26(Suppl 1):32\u201341. https:\/\/doi.org\/10.1111\/jvh.13151.","journal-title":"J Viral Hepat"},{"issue":"8","key":"13791_CR8","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/j.cell.2025.01.033","volume":"188","author":"NA Prescott","year":"2025","unstructured":"Prescott NA, Biaco T, Mansisidor A, et al. A nucleosome switch primes hepatitis B virus infection. Cell. 2025;188(8):2111\u2013e212621. https:\/\/doi.org\/10.1016\/j.cell.2025.01.033.","journal-title":"Cell"},{"issue":"2","key":"13791_CR9","doi-asserted-by":"publisher","first-page":"102446","DOI":"10.1016\/j.jceh.2024.102446","volume":"15","author":"SP Singh","year":"2025","unstructured":"Singh SP, Madke T, Chand P. Global Epidemiology of Hepatocellular Carcinoma. J Clin Exp Hepatol. 2025;15(2):102446. https:\/\/doi.org\/10.1016\/j.jceh.2024.102446.","journal-title":"J Clin Exp Hepatol"},{"issue":"2","key":"13791_CR10","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.dld.2024.10.012","volume":"57","author":"JC Lai","year":"2025","unstructured":"Lai JC, Colombatto P, Wong GL, et al. Why and when could nucleos(t)ide analogues treatment be withdrawn? Dig Liver Dis. 2025;57(2):558\u201363. https:\/\/doi.org\/10.1016\/j.dld.2024.10.012.","journal-title":"Dig Liver Dis"},{"issue":"4","key":"13791_CR11","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1136\/gutjnl-2024-332526","volume":"74","author":"DZ Pan","year":"2025","unstructured":"Pan DZ, Soulette CM, Aggarwal A, et al. Effects of tenofovir disoproxil fumarate on intrahepatic viral burden and liver immune microenvironment in patients with chronic hepatitis B. Gut. 2025;74(4):628\u201338. https:\/\/doi.org\/10.1136\/gutjnl-2024-332526.","journal-title":"Gut"},{"issue":"3","key":"13791_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","volume":"70","author":"TC Yip","year":"2019","unstructured":"Yip TC, Wong GL, Chan HL, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol. 2019;70(3):361\u201370. https:\/\/doi.org\/10.1016\/j.jhep.2018.10.014.","journal-title":"J Hepatol"},{"issue":"1","key":"13791_CR13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1128\/jvi.77.1.68-76.2003","volume":"77","author":"R Thimme","year":"2003","unstructured":"Thimme R, Wieland S, Steiger C, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol. 2003;77(1):68\u201376. https:\/\/doi.org\/10.1128\/jvi.77.1.68-76.2003.","journal-title":"J Virol"},{"issue":"9","key":"13791_CR14","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1038\/s41590-024-01928-4","volume":"25","author":"K Heim","year":"2024","unstructured":"Heim K, Sagar, Sogukpinar \u00d6, et al. Attenuated effector T cells are linked to control of chronic HBV infection. Nat Immunol. 2024;25(9):1650\u201362. https:\/\/doi.org\/10.1038\/s41590-024-01928-4.","journal-title":"Nat Immunol"},{"issue":"8022","key":"13791_CR15","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41586-024-07630-7","volume":"631","author":"M Bosch","year":"2024","unstructured":"Bosch M, Kallin N, Donakonda S, et al. A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection. Nature. 2024;631(8022):867\u201375. https:\/\/doi.org\/10.1038\/s41586-024-07630-7.","journal-title":"Nature"},{"issue":"1","key":"13791_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/gutjnl-2021-325915","volume":"72","author":"C Zhang","year":"2023","unstructured":"Zhang C, Li J, Cheng Y, et al. Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients. Gut. 2023;72(1):153\u201367. https:\/\/doi.org\/10.1136\/gutjnl-2021-325915.","journal-title":"Gut"},{"issue":"1","key":"13791_CR17","doi-asserted-by":"publisher","first-page":"101412","DOI":"10.1016\/j.jcmgh.2024.101412","volume":"19","author":"S Shigeno","year":"2025","unstructured":"Shigeno S, Kodama T, Murai K, et al. Intrahepatic Exhausted Antiviral Immunity in an Immunocompetent Mouse Model of Chronic Hepatitis B. Cell Mol Gastroenterol Hepatol. 2025;19(1):101412. https:\/\/doi.org\/10.1016\/j.jcmgh.2024.101412.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"1","key":"13791_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jhep.2024.02.017","volume":"81","author":"BC Narmada","year":"2024","unstructured":"Narmada BC, Khakpoor A, Shirgaonkar N, et al. Single-cell landscape of functionally cured chronic hepatitis B patients reveals activation of innate and altered CD4-CTL-driven adaptive immunity. J Hepatol. 2024;81(1):42\u201361. https:\/\/doi.org\/10.1016\/j.jhep.2024.02.017.","journal-title":"J Hepatol"},{"issue":"1","key":"13791_CR19","doi-asserted-by":"publisher","first-page":"2463569","DOI":"10.1080\/07853890.2025.2463569","volume":"57","author":"L Tan","year":"2025","unstructured":"Tan L, Mo Z, Gan W, et al. The remodeling of B-cell subsets was correlated with the clearance of hepatitis B antigen during pegylated IFN \u03b1-2a therapy in CHB patients. Ann Med. 2025;57(1):2463569. https:\/\/doi.org\/10.1080\/07853890.2025.2463569.","journal-title":"Ann Med"},{"issue":"1","key":"13791_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s12072-024-10753-8","volume":"19","author":"D Zhu","year":"2025","unstructured":"Zhu D, Du Y, Zhao M, et al. Functional B cell deficiency promotes intrahepatic HBV replication and impairs the development of anti-HBV T cell responses. Hepatol Int. 2025;19(1):93\u2013105. https:\/\/doi.org\/10.1007\/s12072-024-10753-8.","journal-title":"Hepatol Int"},{"issue":"Pt 2","key":"13791_CR21","doi-asserted-by":"publisher","first-page":"126513","DOI":"10.1016\/j.vaccine.2024.126513","volume":"43","author":"TK Berthoud","year":"2025","unstructured":"Berthoud TK, Ahmed T, Nadia W, et al. A three antigen hepatitis B vaccine induces T cells to Pres1 and Pres2 which correlate with anti HBs antibody titers: An investigation into the immunological mechanisms contributing to high anti-HBs titers. Vaccine. 2025;43(Pt 2):126513. https:\/\/doi.org\/10.1016\/j.vaccine.2024.126513.","journal-title":"Vaccine"},{"issue":"1","key":"13791_CR22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nri.2017.106","volume":"18","author":"LL Lu","year":"2018","unstructured":"Lu LL, Suscovich TJ, Fortune SM, et al. Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol. 2018;18(1):46\u201361. https:\/\/doi.org\/10.1038\/nri.2017.106.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"13791_CR23","doi-asserted-by":"publisher","first-page":"100398","DOI":"10.1016\/j.jhepr.2021.100398","volume":"4","author":"T Vanwolleghem","year":"2021","unstructured":"Vanwolleghem T, Adomati T, Van Hees S, et al. Janssen HLA. Humoral immunity in hepatitis B virus infection: Rehabilitating the B in HBV. JHEP Rep. 2021;4(2):100398. https:\/\/doi.org\/10.1016\/j.jhepr.2021.100398.","journal-title":"JHEP Rep"},{"key":"13791_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1146\/annurev-immunol-092419-031130","volume":"38","author":"MP Cancro","year":"2020","unstructured":"Cancro MP, Age-Associated B, Cells. Annu Rev Immunol. 2020;38:315\u201340. https:\/\/doi.org\/10.1146\/annurev-immunol-092419-031130.","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"13791_CR25","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.jhep.2024.06.033","volume":"81","author":"JW Zhang","year":"2024","unstructured":"Zhang JW, Lai RM, Wang LF, et al. Varied immune responses of HBV-specific B cells in patients undergoing pegylated interferon-alpha treatment for chronic hepatitis B. J Hepatol. 2024;81(6):960\u201370. https:\/\/doi.org\/10.1016\/j.jhep.2024.06.033.","journal-title":"J Hepatol"},{"issue":"1","key":"13791_CR26","doi-asserted-by":"publisher","first-page":"5975","DOI":"10.1038\/s41598-024-80903-3","volume":"15","author":"HY Seo","year":"2025","unstructured":"Seo HY, Park JY, Lee SH, et al. Clusterin inhibits lipopolysaccharide induced liver injury. Sci Rep. 2025;15(1):5975. https:\/\/doi.org\/10.1038\/s41598-024-80903-3.","journal-title":"Sci Rep"},{"issue":"4","key":"13791_CR27","doi-asserted-by":"publisher","first-page":"e70022","DOI":"10.1111\/jvh.70022","volume":"32","author":"S Hardtke","year":"2025","unstructured":"Hardtke S, Yurdaydin C, Caruntu FA, et al. Frequency, Severity and Impact of Pegylated Interferon Alpha-Associated Flares in Hepatitis D Infection. J Viral Hepat. 2025;32(4):e70022. https:\/\/doi.org\/10.1111\/jvh.70022.","journal-title":"J Viral Hepat"},{"issue":"3","key":"13791_CR28","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/hep.32400","volume":"76","author":"R Perrillo","year":"2022","unstructured":"Perrillo R, Lin HS, Schwarz KB, et al. Changes in serum hepatitis B surface and e antigen, interferon-inducible protein 10, and aminotransferase levels during combination therapy of immune-tolerant chronic hepatitis B. Hepatology. 2022;76(3):775\u201387. https:\/\/doi.org\/10.1002\/hep.32400.","journal-title":"Hepatology"},{"key":"13791_CR29","unstructured":"Moriles KE, Zubair M, Azer SA. Alanine Aminotransferase (ALT) Test. 2024. PMID: 32644704."},{"issue":"2","key":"13791_CR30","doi-asserted-by":"publisher","first-page":"2259003","DOI":"10.1080\/22221751.2023.2259003","volume":"12","author":"S Yin","year":"2023","unstructured":"Yin S, Wan Y, Issa R, et al. The presence of baseline HBsAb-Specific B cells can predict HBsAg or HBeAg seroconversion of chronic hepatitis B on treatment. Emerg Microbes Infect. 2023;12(2):2259003. https:\/\/doi.org\/10.1080\/22221751.2023.2259003.","journal-title":"Emerg Microbes Infect"},{"issue":"3","key":"13791_CR31","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.virs.2022.03.001","volume":"37","author":"M Li","year":"2022","unstructured":"Li M, Sun F, Bi X, et al. Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients. Virol Sin. 2022;37(3):390\u20137. https:\/\/doi.org\/10.1016\/j.virs.2022.03.001.","journal-title":"Virol Sin"},{"issue":"7","key":"13791_CR32","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1111\/liv.14801","volume":"41","author":"CQ Pan","year":"2021","unstructured":"Pan CQ, Li MH, Yi W, et al. Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens. Liver Int. 2021;41(7):1498\u2013508. https:\/\/doi.org\/10.1111\/liv.14801.","journal-title":"Liver Int"},{"issue":"4","key":"13791_CR33","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1053\/j.gastro.2008.07.008","volume":"135","author":"MF Yuen","year":"2008","unstructured":"Yuen MF, Wong DK, Fung J, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008;135(4):1192\u20139. https:\/\/doi.org\/10.1053\/j.gastro.2008.07.008.","journal-title":"Gastroenterology"},{"issue":"1 Suppl","key":"13791_CR34","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.jhep.2015.02.039","volume":"62","author":"C Trautwein","year":"2015","unstructured":"Trautwein C, Friedman SL, Schuppan D, et al. Hepatic fibrosis: Concept to treatment. J Hepatol. 2015;62(1 Suppl):S15\u201324. https:\/\/doi.org\/10.1016\/j.jhep.2015.02.039.","journal-title":"J Hepatol"},{"issue":"1","key":"13791_CR35","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1038\/s41467-025-56024-4","volume":"16","author":"RA de la Mart\u00ednez Garc\u00eda","year":"2025","unstructured":"de la Mart\u00ednez Garc\u00eda RA, Vallverd\u00fa J, Xu Z, et al. Trajectory analysis of hepatic stellate cell differentiation reveals metabolic regulation of cell commitment and fibrosis. Nat Commun. 2025;16(1):1489. https:\/\/doi.org\/10.1038\/s41467-025-56024-4.","journal-title":"Nat Commun"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13791-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13791-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13791-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T01:25:26Z","timestamp":1789089926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13791-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13791"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13791-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7111922\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"13 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of Beijing Ditan Hospital, Capital Medical University (Approval No.: Jing Di Lun Yan Zi [2023] No. (009)-01). Written informed consent for participation was not required for this study under the national legislation and institutional requirements.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1640"}}